Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.
Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)
Asst. Prof. Shilpa Gupta discusses results from the Bladder Cancer Working Group survey study. The aim of the study is to define criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer (mUC). Platinum-ineligible mUC patients are those who are ineligible for cisplatin and carboplatin treatment and therefore have limited treatment options. Other treatments such as pembrolizumab and atezolizumab are available but restricted to patients who are either ‘platinum ineligible’ or who have high PD-L1 expression. Therefore, a definition of platinum-ineligibility is necessary when deciding on patient treatments, and for determining patients eligibility for clinical trials.
Methods for defining platinum ineligibility
Presented are data from two rounds of survey among genitourinary oncologists. The threshold of criteria such as age, ECOG performance status, creatinine clearance, peripheral neuropathy grade, and heart failure classification are assessed as possible defining factors for Platinum-Ineligibility. Prof. Gupta concludes 5 specified criteria, any one of which would class a patient as platinum-ineligible and thus receive immunotherapy in place of cisplatin and carboplatin. The video and slides aim to provide practical guidance for urologists and we hope you find it of use to your clinical practice.